SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Kueng W)
 

Sökning: WFRF:(Kueng W) > Pooled analysis of ...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00005213naa a2200757 4500
001oai:lup.lub.lu.se:3d865be1-5a19-40bc-b816-c9d1922c96f3
003SwePub
008160401s2002 | |||||||||||000 ||eng|
024a https://lup.lub.lu.se/record/3457802 URI
024a https://doi.org/10.1093/jnci/94.2.1162 DOI
040 a (SwePub)lu
041 a engb eng
042 9 SwePub
072 7a art2 swepub-publicationtype
072 7a ref2 swepub-contenttype
100a Look, MP4 aut
2451 0a Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 8377 breast cancer patients
264 1b Oxford University Press (OUP),c 2002
520 a Background: Urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) play essential roles in tumor invasion and metastasis. High levels of both uPA and PAT-1 are associated with poor prognosis in breast cancer patients. To confirm the prognostic value of uPA and PAI-1 in primary breast cancer, we reanalyzed individual patient data provided by members of the European Organization for Research and Treatment of Cancer-Receptor and Biomarker Group (EORTC-RBG). Methods: The study included 18 datasets involving 8377 breast cancer patients. During follow-up (median 79 months), 35% of the patients relapsed and 27% died. Levels of uPA and PAI-1 in tumor tissue extracts were determined by different immunoassays; values were ranked within each dataset and divided by the number of patients in that dataset to produce fractional ranks that could be compared directly across datasets. Associations of ranks of uPA and PAI-1 levels with relapse-free survival (RFS) and overall survival (OS) were analyzed by Cox multivariable regression analysis stratified by dataset, including the following traditional prognostic variables: age, menopausal status, lymph node status, tumor size, histologic grade, and steroid hormone-receptor status. All P values were two-sided. Results: Apart from lymph node status, high levels of uPA and PAI-1 were the strongest predictors of both poor RFS and poor OS in the analyses of all patients. Moreover, in both lymph node-positive and lymph nodenegative patients, higher uPA and PAI-1 values were independently associated with poor RFS and poor OS. For (untreated) lymph node-negative patients in particular, uPA and PAI-1 included together showed strong prognostic ability (all P<.001). Conclusions: This pooled analysis of the EORTC-RBG datasets confirmed the strong and independent prognostic value of uPA and PAI-1 in primary breast cancer. For patients with lymph node-negative breast cancer, uPA and PAI-1 measurements in primary tumors may be especially useful for designing individualized treatment strategies.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
700a van Putten, WLJ4 aut
700a Duffy, MJ4 aut
700a Harbeck, N4 aut
700a Christensen, IJ4 aut
700a Thomssen, C4 aut
700a Kates, R4 aut
700a Spyratos, F4 aut
700a Fernö, Mårtenu Lund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)onk-mfe
700a Eppenberger-Castori, S4 aut
700a Sweep, CGJF4 aut
700a Ulm, K4 aut
700a Peyrat, JP4 aut
700a Martin, PM4 aut
700a Magdelenat, H4 aut
700a Brunner, N4 aut
700a Duggan, C4 aut
700a Lisboa, BW4 aut
700a Bendahl, Pär-Olau Lund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)onk-pbe
700a Quillien, V4 aut
700a Daver, A4 aut
700a Ricolleau, G4 aut
700a Meijer-van Gelder, E4 aut
700a Manders, P4 aut
700a Fiets, WE4 aut
700a Blankenstein, MA4 aut
700a Broet, P4 aut
700a Romain, S4 aut
700a Daxenbichler, G4 aut
700a Windbichler, G4 aut
700a Cufer, T4 aut
700a Borstnar, S4 aut
700a Kueng, W4 aut
700a Beex, LVAM4 aut
700a Klijn, JGM4 aut
700a O'Higgins, N4 aut
700a Eppenberger, U4 aut
700a Janicke, F4 aut
700a Schmitt, M4 aut
700a Foekens, JA4 aut
710a Bröstcancer-genetikb Sektion I4 org
773t Journal of the National Cancer Instituted : Oxford University Press (OUP)g 94:2, s. 116-128q 94:2<116-128x 1460-2105x 0027-8874
856u http://dx.doi.org/10.1093/jnci/94.2.116x freey FULLTEXT
856u https://academic.oup.com/jnci/article-pdf/94/2/116/9849235/116.pdf
8564 8u https://lup.lub.lu.se/record/345780
8564 8u https://doi.org/10.1093/jnci/94.2.116

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy